A multicentre, open-label, phase 3 study investigating nadofaragene firadenovec for high-grade, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved encouraging, durable, high-grade, recurrence-free (HGRF) survival.
Dr Neal Shore (Carolina Urologic Research Center, USA) presented the outcomes of the papillary disease (PD) cohort from the trial . Nadofaragene firadenovec is a novel intravesical-administered adenovirus-mediated gene therapy (rAd-IFN) delivering the human *interferon (IFN) α2b gene*. When combined with the excipient Syn3, rAd-IFN/Syn3 has been shown in a phase 2 trial to be well tolerated and leads to sustained localised *IFNα2b* gene expression.
The phase 3 trial enrolled 157 patients (mean age 71 years), 50 of whom had PD. Intravesical administration of nadofaragene firadenovec (3×1011 viral particles/mL [75 mL]) was...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Reduced BCG frequency, faster NMIBC recurrence Next Article
Understanding MIBC biology for novel treatment options »
Table of Contents: EAU 2020
Surgical Techniques and Safety
Prostate Cancer & Imaging
BPH & LUTS
Testis Cancer & Andrology
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.